**LIST OF SUPPLEMENTAL DIGITAL CONTENT**

* **Supplemental Digital Content 1*.*** Figure that illustrates priority populations for ACTIV.
* **Supplemental Digital Content 2*.*** Figure that illustrates modified review criteria for Waves 2 and beyond.
* **Supplemental Digital Content 3.** Figure that illustrates agent assignment categories post review by ACTIV.
* **Supplemental Digital Content 4.** Figure that illustrates the original neutralizing antibody review criteria and revision process.
* **Supplemental Digital Content 5.** Repurposed figure with permission from Menetski, JP from Cell Host Microbe. 2020 Nov 11;28(5):638-645. doi: 10.1016/j.chom.2020.09.017. Epub 2020 Oct 1. that illustrates coordination of agent review with Preclinical Working Group.
* **Supplemental Digital Content 6.** Review criteria for widely available repurposed agents for outpatient treatment of COVID 19 To effectively and efficiently evaluate the COVID 19 therapeutic potential of widely available, mostly generic repurposed agents, the ACTIV agent prioritization subteam defined a set of triage, “must have”, and “nice to have” criteria. Two triage criteria safety and route of administration are established to focus on candidates with sufficient safety data and are easily stored and administered. This would ensure that the prioritized candidates are appropriate to be investigated in a mostly remotely condu cte d trial. “Must have” criteria include considerations around the candidate’s mechanism of action and its relevancy for COVID 19, early clinical evidence or real world evidence in the context of COVID 19, and potential drug drug interaction concerns. Notably, the ACTIV agent prioritization subteam recognized that a wholistic approach needs to be taken when evaluating relevant clinical trial data, so that a wide range of study designs and outcomes can be considered in an integrative manner. In addit ion to the aforementioned criteria, the ACTIV agent prioritization subteam also deemed preclinical data, pharmacokinetics / pharmacodynamics, and level of public / scientific interest as relevant revi ew criteria as “nice to haves”. Finally, a vailability / scalability of the candidate will be assessed after prioritization of any agent before official entry into the tri al. ACTIV Accelerating COVID 19 Therapeutic Interventions and Vaccines IV = intravenous, PD = pharmacodynamics, PK = pharmacokinetics, RCT = randomized controlled trial, SARS CoV 2 Severe Acute Respiratory Syndrome Coronavirus 2, SubQ = subcutaneous.